Methods of inhibiting prmt5
US-2015344457-A1 · Dec 3, 2015 · US
CARM1 inhibitors and uses thereof
US9856267B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9856267-B2 |
| Application number | US-201715648701-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 13, 2017 |
| Priority date | Mar 15, 2013 |
| Publication date | Jan 2, 2018 |
| Grant date | Jan 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 1a , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is: or a pharmaceutically acceptable salt thereof. 2. A compound which is: 3. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 1 and a pharmaceutically acceptable excipient. 4. A pharmaceutical composition comprising the compound according to claim 2 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Immunomodulators · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
One nitrogen atom (nitro radicals C07D239/30) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9856267B2 cover?
- Provided herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 1a , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula: wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as …
- Who is the assignee on this patent?
- Epizyme Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).